Qiagen

Ansa Bio Appoints Dr. Matthew McManus as Chair of the Board

Retrieved on: 
Wednesday, February 22, 2023
Other Health, Software, Research, Pharmaceutical, Hardware, Data Management, Technology, Genetics, Clinical Trials, Science, Biotechnology, Health, Medicine, Agriculture, University, DNA, MBA, Holy Cross, Acquisition, Independent director, Growth, Economics, College of the Holy Cross, Multimedia, Chairperson, Qiagen, EVP, Management, Boston College, Azenta, Bio-Techne

Ansa Biotechnologies , a pioneer of next-generation DNA synthesis, today announced the appointment of Matthew F. McManus, M.D, Ph.D., as Independent Director and Chairperson of the company’s Board of Directors.

Key Points: 
  • Ansa Biotechnologies , a pioneer of next-generation DNA synthesis, today announced the appointment of Matthew F. McManus, M.D, Ph.D., as Independent Director and Chairperson of the company’s Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20230222005146/en/
    Dr. McManus brings decades of experience in the life sciences industry to the Board.
  • “We’re thrilled to welcome Matt to the Board as we enter our next stage of growth,” said Daniel Lin-Arlow, CEO & Co-Founder.
  • “I am honored to have the opportunity to work with the Ansa Bio team to help realize this potential.”
    Dr. McManus received his M.D.

Global KRAS Inhibitors Market Report to 2029: Featuring Ascentage Pharma, AstraZeneca, Boehringer Ingelheim and BridgeBio Pharma Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 9, 2023
Biotechnology, Pharmaceutical, Health, FIRST, Mirati Therapeutics, Oncogene, Biology, Diagnosis, Patient, Sale, Adagrasib, Research, Neoplasm, Sotorasib, RAS, KRAS, Lung cancer, Amgen, FDA, Growth, Qiagen, Creativity, NSCLC, Cancer, Pharmaceutical industry

KRAS is one such oncogene that is the most frequently mutated and therefore, specific research and clinical activities are being carried out for the possible development of novel KRAS inhibitors.

Key Points: 
  • KRAS is one such oncogene that is the most frequently mutated and therefore, specific research and clinical activities are being carried out for the possible development of novel KRAS inhibitors.
  • The future pipeline of this target looks flourishing as several pharmaceutical companies also plan on bringing novel drug candidates against KRAS.
  • Researchers worldwide have known about KRAS mutations for several years; however, the available therapies against it were proven to be indefinable.
  • It is both interesting and concerning how KRAS mutations play a significant role in the pathogenesis and proliferation of cancer.

United States Hereditary Genetic Testing Market Analysis and Forecasts, 2022-2032 with Laboratory Corporation of America Holdings, Quest Diagnostics, & F. Hoffmann-La Roche Dominating - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Health, Genetics, Genetic testing, LabCorp, Parkinson's disease, Heredity, Brain, Ascension, Benchmarking, Illumina, Inc., LRRK2, Epidemiology, Partnership, Genetic, Growth, Qiagen, Drug discovery, Prevalence, Software, Research, Cancer, Agriculture, Pharmaceutical industry, Vaccine, Audit, Medical imaging

Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • Among application area, all the four sub-segments constitute an almost equal share in the U.S. hereditary genetic testing market.
  • Hereditary Genetic Testing Market
    On 3 October 2022, Laboratory Corporation of America Holdings concluded the transactions, establishing a long-term laboratory connection with Ascension.
  • The following companies had a total market share of over 25% in 2021 and were highly active in the U.S. hereditary genetic testing market:

ARCH Venture Partners Announces Patrick Weiss as Venture Partner

Retrieved on: 
Thursday, December 8, 2022
Publication, Organic chemistry, Swiss Federal Institute of Technology, Patrick, Federal Institute of Science and Technology, Lightspeed Venture Partners, Sirna, DNA, Swiss, ARCH, Twist, Twist Bioscience, Mentorship, Gene silencing, Economics, ETH, Qiagen, RNA, Dam, Fine chemical, Pharmaceutical industry

CHICAGO, Dec. 8, 2022 /PRNewswire/ -- ARCH Venture Partners, one of the world's leading early-stage technology venture firms, today announced the appointment of life sciences industry veteran Patrick Weiss as Venture Partner.

Key Points: 
  • CHICAGO, Dec. 8, 2022 /PRNewswire/ -- ARCH Venture Partners, one of the world's leading early-stage technology venture firms, today announced the appointment of life sciences industry veteran Patrick Weiss as Venture Partner.
  • "Building on nearly a decade of working with Patrick, we are extremely pleased to have him join the ARCH team.
  • Patrick will add further to those important capabilities," said ARCH Co-founder and Managing Director Keith Crandell.
  • ARCH Venture Partners invests in advanced technology companies and is one of the largest early-stage technology venture firms in the United States.

miRNA Sequencing and Assay Market Report 2022: Rise in Adoption of RNA Sequencing Protocols in Biotechnology Research Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022
Health, Biotechnology, Nervous system, Sepsis, Workflow, Product-service system, Thermo Fisher Scientific, Qiagen, Prognosis, Research, Cancer, RNA, Mirna, Ion semiconductor sequencing, Growth, Breast, Mutation, MicroRNA, Illumina, Inc., PerkinElmer, Partnership, Biomarker, Diagnosis, Degenerative disease, Application, USD, Medical imaging, Video game console

The global miRNA sequencing and assay market size is expected to reach USD 823.5 million by 2030.

Key Points: 
  • The global miRNA sequencing and assay market size is expected to reach USD 823.5 million by 2030.
  • The market is expected to register a CAGR of 13.25% from 2022 to 2030 owing to the growing application areas of miRNA sequencing in the healthcare sector.
  • Furthermore, these companies have entered into several strategic initiatives with research institutes to expand the sequencing application in research studies.
  • It has become a key research tool in biological research and several disease diagnoses
    By application, cancer dominated the market in 2021.

Europe Biopsy Devices Market Analysis Report 2022: Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022
Health, Oncology, COVID-19, Incidence, Genomics, Biopsy, Diagnosis, Infection, Economy of the European Union, Cell, Bio-Rad Laboratories, Hospital, Roche Diagnostics, Ultrasound-guided hip joint injection, MI, Patient, Thermo Fisher Scientific, Becton, Cancer, Quest Diagnostics, Prostate, MRI, Lung cancer, Becton, Dickinson and Company headquarters, Imaging, Surgeon, Radiology, Research, Prostate cancer, Exact sciences, Insight, Association for Molecular Pathology v. Myriad Genetics, Inc., Cardiology, Liquid biopsy, Breast cancer, Investment, CT, Qiagen, Medical imaging, Pharmaceutical industry, Coronavirus, Growth

The "Europe Biopsy Devices Market, Size, Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Biopsy Devices Market, Size, Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Biopsy guiding systems, needle-based biopsy guns, biopsy needles, and biopsy forceps are the most often used biopsy instruments.
  • Increased investments in R&D activities are driving the Europe Biopsy Devices Market.
  • According to our analysis, the Europe Biopsy Devices Market was negatively impacted from the end of 2019 to the beginning of 2020.

U.S. hereditary genetic testing market was valued at $7.57 billion in 2021 and is expected to grow with a CAGR of 13.09% and reach $29.28 billion by 2032

Retrieved on: 
Monday, November 28, 2022
Software, Growth, LabCorp, Parkinson's disease, Partnership, LRRK2, Epidemiology, Illumina, Inc., Genetic testing, Research, Ascension, Benchmarking, Drug discovery, Qiagen, Vaccine, Medical imaging, Pharmaceutical industry

View original content:https://www.prnewswire.com/news-releases/us-hereditary-genetic-testing-m...

Key Points: 
  • Among application area, all the four sub-segments constitute an almost equal share in the U.S. hereditary genetic testing market.
  • Hereditary Genetic Testing Market
    On 3 October 2022, Laboratory Corporation of America Holdings concluded the transactions, establishing a long-term laboratory connection with Ascension.
  • Competitive Strategy: The report provides insight into the existing competition in the U.S. hereditary genetic testing market.
  • The following companies had a total market share of over 25% in 2021 and were highly active in the U.S. hereditary genetic testing market:

United States Liquid Biopsy Market Report 2022: Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 25, 2022
Biotechnology, Health, Oncology, COVID-19, Liquid biopsy, EVS, Genomics, Diagnosis, Laboratory, Blood, DNA, Hospital, Urine, Roche Diagnostics, Projection, Circulating tumor DNA, Patient, Liquid, Government, Association for Molecular Pathology v. Myriad Genetics, Inc., Thermo Fisher Scientific, Biomarker, Exosome, Organic acid, American Cancer Society, Lung cancer, Chinese, Colorectal cancer, Prognosis, Cancer, Neoplasm, Research, Prostate cancer, Exact sciences, MBS, Coronavirus, Extracellular vesicle, Breast cancer, Large-cell lung carcinoma, Woman, Infection, Qiagen, Person, Medical imaging, Glossary of biology, Growth

The "United States Liquid Biopsy Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Liquid Biopsy Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • However, the reduced sensitivity of some liquid biopsies may limit market growth in the United States throughout the foreseeable period.
  • The liquid biopsy market in the United States is split into four categories: lung cancer, breast cancer, colorectal cancer, and prostate cancer.
  • The liquid biopsy market in the United States is classified into three categories: kits and consumables, instruments, and services.

SeQure Dx Emerges From Stealth Mode to Fulfill the Promise of On-Target Gene Editing Therapies for Biopharma Partners, Physicians, and Patients

Retrieved on: 
Wednesday, November 16, 2022
Medical Supplies, Biotechnology, FDA, Health, Pharmaceutical, Medical Devices, Research, Hospitals, Genetics, Science, Clinical Trials, Massachusetts General Hospital, Safety, Coronavirus Scientific Advisory Board (Turkey), Optimism, Risk, MD, United States Navy, CFO, Qiagen, Doctor of Philosophy, Research, CMO, Harvard Medical School, CSO, Assistant, Computational biology, Dana–Farber Cancer Institute, FDA, MIT, Data science, Investment, Entrepreneurship, Quest Diagnostics, Editas Medicine, IND, Therapy, MBA, Hospital, Gene editing, Genomics, Broad Institute, Patient safety, MGH, CBO, CRISPR, Lymphatic system, Harvard University, Associate, Foundation Medicine, Mass, Medical device, Pharmaceutical industry, Vaccine, Management, Biostatistics, Pathology

SeQure Dx, a cutting-edge gene editing diagnostics company, has announced its emergence from stealth mode with an aim to partner with biopharma companies developing gene editing therapeutics.

Key Points: 
  • SeQure Dx, a cutting-edge gene editing diagnostics company, has announced its emergence from stealth mode with an aim to partner with biopharma companies developing gene editing therapeutics.
  • SeQure Dxs platform comprises the only scalable, population-based and editing technology-agnostic in vitro off-target evaluation method complemented by orthogonal methods required for off-target risk validation.
  • Evaluating potential off-target edits created by these therapies plays an enormous role in the advancement of safe and effective gene editing.
  • Quickly, the optimism was tempered by the discovery that off target editing is a companion effect for all the gene editing methods conceived so far.

Infectious Respiratory Disease Diagnostics Market Report 2022: Rising R&D Investments In Respiratory Disease Testing Boost Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, October 31, 2022
Infectious Diseases, Biotechnology, Health, Quidel Corporation, Diagnosis, Application, USD, IVD, Danaher, Industry, UN, COVID-19 testing, RSV, D, Pneumonia, COVID-19, Disease, BD, Technology, Infection, Growth, Tuberculosis, Qiagen, Revenue, Prevalence, Incidence, Laboratory, Medical device, Pharmaceutical industry, Vaccine

The global infectious respiratory disease diagnostic market size is expected to reach USD 43.74 billion by 2030 according to a new study.

Key Points: 
  • The global infectious respiratory disease diagnostic market size is expected to reach USD 43.74 billion by 2030 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
  • For instance, in April 2020, 6.08 million people across globe were infected with COVID-19 diseases, which increased the need for rapid diagnostics testing is likely to boost the infectious respiratory disease diagnostic market.
  • The publisher has segmented the infectious respiratory disease diagnostics market report based on, technology, product, application, work-flow, end-use, and regions:
    Infectious Respiratory Disease Diagnostics, Product Type Outlook (Revenue - USD Billion, 2018 - 2030)